Nucleotide News and Research

RSS

Researchers use healthy person's complete genome sequence to predict risk for dozens of diseases

For the first time, researchers have used a healthy person's complete genome sequence to predict his risk for dozens of diseases and how he will respond to several common medications. The risk analysis, from the Stanford University School of Medicine, also incorporates more-traditional information such as a patient's age and gender and other clinical measurements.

30 Apr 2010

NWO awards 31 grants in Investment Subsidy NWO Medium programme

The Netherlands Organisation for Scientific Research (NWO) has awarded 31 grants in the Investment Subsidy NWO Medium programme for the acquisition of equipment, the setting up of data collections and the production of software and bibliographies. The total investment amounts to 10 million euro.

30 Apr 2010

Researchers study effects of low-moderate alcohol consumption on bone health in women

For as long as our ancestors have been drawing pictograms or writing prose about food and culture, humans have been imbibing various forms of alcohol. Once simply a process by which nutritious beverages could be preserved and stored for later use, there is no doubt that the production and consumption of wines, beers, and spirits now provides integral texture to the fabric of many cultures.

30 Apr 2010

Genes that predispose to smoking behavior and lung cancer identified: More reason to quit say researchers

According to new research there are certain genes in a smoker that make it difficult for them to cut down or quit the bad habit. This report from three studies published in the journal Nature Genetics mentions at least three different genetic mutations on chromosome 15 or changes that can increase the number of cigarettes smoked per day by an individual.

25 Apr 2010

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.

22 Apr 2010

People with vitiligo may have less risk of developing malignant melanoma: Research

People with the skin pigmentation disorder vitiligo may have less risk of developing life-threatening malignant melanoma, according to new research. The study also further confirms the suspicion that vitiligo is an autoimmune disease, which occur when the body's immune system reacts against its own tissues or organs.

22 Apr 2010

Systems biologists integrate new genetic framework to help predict adverse drug reactions

In a major step toward predicting adverse drug reactions, systems biologists at Mount Sinai School of Medicine in New York City have integrated genetic, cellular and clinical information to find out why certain medicines can trigger fatal heart arrhythmias.

21 Apr 2010

Life Technologies introduces new ViiA 7 Real-Time PCR System

Life Technologies Corporation today announced the expansion of its industry-leading family of real-time PCR systems with the introduction of a new high-productivity instrument. The Applied Biosystems ViiA™ 7 Real-Time PCR System seamlessly integrates a variety of quantitative PCR (qPCR) and genotyping applications, enabling researchers to enter a new era of lab productivity.

20 Apr 2010

Investment report on Idenix Pharmaceuticals

StockPreacher.com announces an investment report featuring Idenix Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

16 Apr 2010

New therapeutic approach for Duchenne muscular dystrophy

Researchers from Universit- Laval's Faculty of Medicine and the CHUQ Research Center have proven that it is possible to repair the defective gene responsible for Duchenne muscular dystrophy.

16 Apr 2010

New findings may allow clinicians to prevent complications in pregnancy

Researchers at Mount Sinai School of Medicine have found that epigenetic marks on human placentas change from the first trimester of pregnancy to the third, a discovery that may allow clinicians to prevent complications in pregnancy.

15 Apr 2010

Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV

Pharmasset, Inc. announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in patients with hepatitis C virus (HCV) genotype 1 who have not been treated previously.

15 Apr 2010

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 14-day, phase IIa clinical trial evaluating IDX184, a novel liver-targeted nucleotide prodrug of 2'-methyl guanosine monophosphate, in HCV-infected patients.

15 Apr 2010

Gene playing crucial role in immune system balance identified

A team led by St. Jude researchers identified a gene pivotal for immune system balance. Ultimately, the discovery may aid efforts to tame allergies and asthma.

12 Apr 2010

Ku protein employs unique mechanism for DNA repair: Researchers

Scientists have shown in multiple contexts that DNA damage over our lifetimes is a key mechanism behind the development of cancer and other age-related diseases. Not everyone gets these diseases, because the body has multiple mechanisms for repairing the damage caused to DNA by aging, the environment and other human behaviors - but the mechanisms behind certain kinds of DNA repair have not been well-understood.

12 Apr 2010

Phase 1 SAD study of PSI-938 for HCV initiated

Pharmasset, Inc. announced today that dosing has initiated in a phase 1, single ascending dose study in healthy volunteers with PSI-938, a third generation purine nucleotide analog polymerase inhibitor of hepatitis C virus. Pharmasset recently filed an Investigational New Drug Application with the Food and Drug Administration.

8 Apr 2010

USPTO allows Alnylam Pharmaceuticals' new claims from Woppmann et al. patent series

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent Office (USPTO) has allowed a patent (Application No. 10/560,336) for the Woppmann et al. patent series, entitled "Double-stranded ribonucleic acid with increased effectiveness in an organism." The newly allowed patent includes 31 claims broadly covering compositions and methods, including pharmaceutical compositions, for small interfering RNAs (siRNAs), the molecules that mediate RNAi.

8 Apr 2010

Nucleotide News and Research

Researchers use healthy person's complete genome sequence to predict risk for dozens of diseases

NWO awards 31 grants in Investment Subsidy NWO Medium programme

Researchers study effects of low-moderate alcohol consumption on bone health in women

Genes that predispose to smoking behavior and lung cancer identified: More reason to quit say researchers

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

People with vitiligo may have less risk of developing malignant melanoma: Research

Systems biologists integrate new genetic framework to help predict adverse drug reactions

Life Technologies introduces new ViiA 7 Real-Time PCR System

Investment report on Idenix Pharmaceuticals

New therapeutic approach for Duchenne muscular dystrophy

New findings may allow clinicians to prevent complications in pregnancy

Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Gene playing crucial role in immune system balance identified

Ku protein employs unique mechanism for DNA repair: Researchers

Phase 1 SAD study of PSI-938 for HCV initiated

USPTO allows Alnylam Pharmaceuticals' new claims from Woppmann et al. patent series

CAV1 gene variation contributes to kidney transplant failure: JAMA

Gene duplications can lead to functional diversity in organisms

Neogen announces acquisition of GeneSeek

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News